乌布吉泮与安慰剂对偏头痛急性治疗中疼痛及最困扰伴随症状的疗效:ACHIEVE II随机临床试验
该3期多中心随机双盲安慰剂对照单次发作试验在美国99家诊所纳入1686例成人偏头痛患者,比较乌布吉泮50mg、25mg与安慰剂。结果显示50mg和25mg组2小时无痛率均显著高于安慰剂,但仅50mg组最困扰伴随症状消失率显著优于安慰剂。
要点
- 乌布吉泮50mg和25mg组2小时无痛率均显著高于安慰剂组。
- 仅乌布吉泮50mg组2小时最困扰伴随症状消失率显著优于安慰剂。
- 常见不良事件为恶心和头晕,各组发生率相近。
核心结论
- 在成人偏头痛患者中,乌布吉泮50mg和25mg急性治疗较安慰剂显著提高2小时无痛率,但仅50mg剂量显著提高2小时最困扰偏头痛伴随症状消失率。
研究设计与样本
- 3期、多中心、随机、双盲、安慰剂对照、单次发作临床试验(ACHIEVE II),在美国99家初级保健和研究诊所开展,时间为2016年8月26日至2018年2月26日。
- 纳入每月发作2至8次、伴或不伴先兆的成人偏头痛患者,随机接受乌布吉泮50mg(n=562)、乌布吉泮25mg(n=561)或安慰剂(n=563)治疗中重度疼痛的偏头痛发作。
主要发现
- 1686例随机参与者中1465例接受研究治疗(安全性人群;平均年龄41.5岁;90%女性),其中1355例(92.5%)可评估疗效。
- 2小时无痛率:乌布吉泮50mg组101/464(21.8%),25mg组90/435(20.7%),安慰剂组65/456(14.3%);50mg vs 安慰剂绝对差值7.5%(95%CI 2.6%-12.5%;P=.01),25mg vs 安慰剂绝对差值6.4%(95%CI 1.5%-11.5%;P=.03)。
- 2小时最困扰伴随症状消失率:乌布吉泮50mg组180/463(38.9%),25mg组148/434(34.1%),安慰剂组125/456(27.4%);50mg vs 安慰剂绝对差值11.5%(95%CI 5.4%-17.5%;P=.01),25mg vs 安慰剂绝对差值6.7%(95%CI 0.6%-12.7%;P=.07)。
- 任何剂量给药后48小时内最常见不良事件为恶心(50mg组10/488[2.0%];25mg组12/478[2.5%];安慰剂组10/499[2.0%])和头晕(50mg组7/488[1.4%];25mg组10/478[2.1%];安慰剂组8/499[1.6%])。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步研究评估乌布吉泮与其他偏头痛急性治疗药物的有效性。
- 需要进一步研究评估乌布吉泮在未经选择的患者人群中的长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ubrogepant is an oral calcitonin gene-related peptide receptor antagonist under investigation for acute treatment of migraine. OBJECTIVE: To evaluate the efficacy and tolerability of ubrogepant compared with placebo for acute treatment of a single migraine attack. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, multicenter, randomized, double-blind, placebo-controlled, single-attack, clinical trial (ACHIEVE II) conducted in the United States (99 primary care and research clinics; August 26, 2016-February 26, 2018). Participants were adults with migraine with or without aura experiencing 2 to 8 migraine attacks per month. INTERVENTIONS: Ubrogepant 50 mg (n = 562), ubrogepant 25 mg (n = 561), or placebo (n = 563) for a migraine attack of moderate or severe pain intensity. MAIN OUTCOMES AND MEASURES: Co-primary efficacy outcomes were pain freedom and absence of the participant-designated most bothersome migraine-associated symptom (among photophobia, phonophobia, and nausea) at 2 hours after taking the medication. RESULTS: Among 1686 randomized participants, 1465 received study treatment (safety population; mean age, 41.5 years; 90% female); 1355 of 1465 (92.5%) were evaluable for efficacy. Pain freedom at 2 hours was reported by 101 of 464 participants (21.8%) in the ubrogepant 50-mg group, 90 of 435 (20.7%) in the ubrogepant 25-mg group, and 65 of 456 (14.3%) in the placebo group (absolute difference for 50 mg vs placebo, 7.5%; 95% CI, 2.6%-12.5%; P = .01; 25 mg vs placebo, 6.4%; 95% CI, 1.5%-11.5%; P = .03). Absence of the most bothersome associated symptom at 2 hours was reported by 180 of 463 participants (38.9%) in the ubrogepant 50-mg group, 148 of 434 (34.1%) in the ubrogepant 25-mg group, and 125 of 456 (27.4%) in the placebo group (absolute difference for 50 mg vs placebo, 11.5%; 95% CI, 5.4%-17.5%; P = .01; 25 mg vs placebo, 6.7%; 95% CI, 0.6%-12.7%; P = .07). The most common adverse events within 48 hours of any dose were nausea (50 mg, 10 of 488 [2.0%]; 25 mg, 12 of 478 [2.5%]; and placebo, 10 of 499 [2.0%]) and dizziness (50 mg, 7 of 488 [1.4%]; 25 mg, 10 of 478 [2.1%]; placebo, 8 of 499 [1.6%]). CONCLUSIONS AND RELEVANCE: Among adults with migraine, acute treatment with ubrogepant compared with placebo led to significantly greater rates of pain freedom at 2 hours with 50-mg and 25-mg doses, and absence of the most bothersome migraine-associated symptom at 2 hours only with the 50-mg dose. Further research is needed to assess the effectiveness of ubrogepant against other acute treatments for migraine and to evaluate the long-term safety of ubrogepant among unselected patient populations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02867709.
引用
- Lipton RB, Dodick DW, Ailani J, et al. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019. PMID: 31742631. doi:10.1001/jama.2019.16711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。